ArQule Shares Outstanding 2006-2018 | ARQL

ArQule shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • ArQule shares outstanding for the quarter ending June 30, 2018 were 0.101B, a 41.3% increase year-over-year.
  • ArQule 2017 shares outstanding were 0.075B, a 7.31% increase from 2016.
  • ArQule 2016 shares outstanding were 0.07B, a 11% increase from 2015.
  • ArQule 2015 shares outstanding were 0.063B, a 0.29% increase from 2014.
ArQule Annual Shares Outstanding
(Millions of Shares)
2017 75
2016 70
2015 63
2014 63
2013 62
2012 60
2011 53
2010 45
2009 44
2008 44
2007 40
2006 36
2005 35
ArQule Quarterly Shares Outstanding
(Millions of Shares)
Q2 2018 101
Q1 2018 87
Q4 2017 75
Q3 2017 72
Q2 2017 71
Q1 2017 71
Q4 2016 70
Q3 2016 71
Q2 2016 71
Q1 2016 65
Q4 2015 63
Q3 2015 63
Q2 2015 63
Q1 2015 63
Q4 2014 63
Q3 2014 63
Q2 2014 63
Q1 2014 63
Q4 2013 62
Q3 2013 63
Q2 2013 62
Q1 2013 62
Q4 2012 60
Q3 2012 62
Q2 2012 61
Q1 2012 54
Q4 2011 53
Q3 2011 54
Q2 2011 53
Q1 2011 51
Q4 2010 45
Q3 2010 45
Q2 2010 45
Q1 2010 44
Q4 2009 44
Q3 2009 44
Q2 2009 44
Q1 2009 44
Q4 2008 44
Q3 2008 44
Q2 2008 44
Q1 2008 44
Q4 2007 40
Q3 2007 44
Q2 2007 37
Q1 2007 36
Q4 2006 36
Q3 2006 36
Q2 2006 35
Q1 2006 35
Q4 2005 35
Q3 2005 35
Q2 2005 35
Q1 2005 33
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.470B $0.005B
ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.
Stock Name Country Market Cap PE Ratio
Shire (SHPG) Ireland $53.195B 11.27
Zoetis (ZTS) United States $44.072B 31.98
Tilray (TLRY) United States $13.534B 0.00
Grifols (GRFS) Spain $13.213B 16.13
Neurocrine Biosciences (NBIX) United States $10.133B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $9.423B 13.87
Nektar Therapeutics (NKTR) United States $8.311B 9.72
Ionis Pharmaceuticals (IONS) United States $6.203B 0.00
Catalent (CTLT) United States $6.007B 25.86
Sage Therapeutics (SAGE) United States $5.708B 0.00
Impax Laboratories (AMRX) United States $5.590B 29.73
United Therapeutics (UTHR) United States $5.356B 6.88
Loxo Oncology (LOXO) United States $4.875B 0.00
FibroGen (FGEN) United States $4.461B 0.00
Endo (ENDP) Ireland $3.926B 5.64
Taro Pharmaceutical Industries (TARO) Israel $3.745B 14.50
Madrigal Pharmaceuticals (MDGL) United States $2.958B 0.00
Aerie Pharmaceuticals (AERI) United States $2.640B 0.00
Ironwood Pharmaceuticals (IRWD) United States $2.559B 0.00
USANA Health Sciences (USNA) United States $2.532B 22.31
TESARO (TSRO) United States $2.292B 0.00
Heron Therapeutics (HRTX) United States $2.264B 0.00
Xencor (XNCR) United States $1.955B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.925B 0.00
PTC Therapeutics (PTCT) United States $1.910B 0.00
Endocyte (ECYT) United States $1.651B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.605B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.530B 18.71
Zogenix (ZGNX) United States $1.488B 0.00
Portola Pharmaceuticals (PTLA) United States $1.448B 0.00
Corcept Therapeutics (CORT) United States $1.412B 21.73
Spectrum Pharmaceuticals (SPPI) United States $1.397B 0.00
TherapeuticsMD (TXMD) United States $1.269B 0.00
Tricida (TCDA) United States $1.265B 0.00
Esperion Therapeutics (ESPR) United States $1.206B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $1.149B 0.00
ImmunoGen (IMGN) United States $1.107B 0.00
Radius Health (RDUS) United States $0.862B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.785B 0.00
Karyopharm Therapeutics (KPTI) United States $0.743B 0.00
Flexion Therapeutics (FLXN) United States $0.716B 0.00
GlycoMimetics (GLYC) United States $0.609B 0.00
Dova Pharmaceuticals (DOVA) United States $0.582B 0.00
ChemoCentryx (CCXI) United States $0.574B 33.56
Dermira (DERM) United States $0.550B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.549B 0.00
Collegium Pharmaceutical (COLL) United States $0.545B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.496B 0.00
Akebia Therapeutics (AKBA) United States $0.492B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.474B 0.00
OptiNose (OPTN) United States $0.470B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.456B 31.09
Forty Seven (FTSV) United States $0.451B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.424B 0.00
Xeris Pharmaceuticals (XERS) United States $0.415B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.415B 0.00
Odonate Therapeutics (ODT) United States $0.411B 0.00
Minerva Neurosciences (NERV) United States $0.410B 0.00
Siga Technologies (SIGA) United States $0.401B 0.00
Aclaris Therapeutics (ACRS) United States $0.387B 0.00
Zafgen (ZFGN) United States $0.382B 0.00
Depomed (ASRT) United States $0.368B 0.00
Aquestive Therapeutics (AQST) United States $0.358B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.354B 0.00
Synergy Pharmaceuticals (SGYP) United States $0.352B 0.00
Concert Pharmaceuticals (CNCE) United States $0.347B 0.00
ElectroCore (ECOR) United States $0.341B 0.00
KalVista Pharmaceuticals (KALV) United States $0.340B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.340B 0.00
Mast Therapeutics (SVRA) United States $0.333B 0.00
Majesco Entertainment (PTE) United States $0.275B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.270B 0.00
MEI Pharma (MEIP) United States $0.267B 0.00
CASI Pharmaceuticals (CASI) United States $0.265B 0.00
Translate Bio (TBIO) United States $0.263B 0.00
Aratana Therapeutics (PETX) United States $0.256B 0.00
IMV INC (IMV) Canada $0.252B 0.00
Neon Therapeutics (NTGN) United States $0.250B 0.00
Aldeyra Therapeutics (ALDX) United States $0.250B 0.00
Opexa Therapeutics (ACER) United States $0.246B 0.00
Ardelyx (ARDX) United States $0.241B 0.00
Tyme Technologies (TYME) United States $0.241B 0.00
Ocular Therapeutix (OCUL) United States $0.238B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.232B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.225B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.220B 0.00
Melinta Therapeutics (MLNT) United States $0.212B 0.00
Galectin Therapeutics (GALT) United States $0.202B 0.00
Affimed (AFMD) Germany $0.200B 0.00
Calithera Biosciences (CALA) United States $0.187B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.184B 0.00
Jounce Therapeutics (JNCE) United States $0.182B 0.00
Achaogen (AKAO) United States $0.181B 0.00
Redhill Biopharma (RDHL) Israel $0.179B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.174B 0.00
Molecular Templates (MTEM) United States $0.171B 0.00
DURECT (DRRX) United States $0.168B 0.00
MediWound (MDWD) Israel $0.164B 0.00
Nature's Sunshine Products (NATR) United States $0.159B 0.00
Zomedica Pharmaceuticals (ZOM) United States $0.156B 0.00
ContraFect (CFRX) United States $0.152B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.151B 0.00
Lannett Co Inc (LCI) United States $0.151B 1.25
Recro Pharma (REPH) United States $0.150B 0.00
Infinity Pharmaceuticals (INFI) United States $0.145B 0.00
Adherex Technologies (FENC) United States $0.143B 0.00
Champions Oncology (CSBR) United States $0.143B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.139B 0.00
ProNAi Therapeutics (SRRA) Canada $0.132B 0.00
Neos Therapeutics (NEOS) United States $0.123B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.123B 0.00
India Globalization Capital (IGC) United States $0.116B 0.00
Cardiome Pharma (CORV) Canada $0.115B 0.00
Rafael Holdings (RFL) United States $0.112B 0.00
CTI BioPharma (CTIC) United States $0.112B 0.00
BioLineRx (BLRX) Israel $0.104B 0.00
Forward Pharma (FWP) Denmark $0.100B 0.00
ENTASIS THERAPT (ETTX) United States $0.097B 0.00
Iterum Therapeutics (ITRM) Ireland $0.088B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.085B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.085B 0.00
Immune Design (IMDZ) United States $0.080B 0.00
Otonomy (OTIC) United States $0.080B 0.00
Actinium Pharmaceuticals (ATNM) United States $0.079B 0.00
Natural Alternatives (NAII) United States $0.071B 7.95
Nivalis Therapeutics (ALPN) United States $0.069B 0.00
Novan (NOVN) United States $0.065B 0.00
Genocea Biosciences (GNCA) United States $0.063B 0.00
Trillium Therapeutics (TRIL) Canada $0.054B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.051B 40.98
SCYNEXIS (SCYX) United States $0.048B 0.00
Mannatechorporated (MTEX) United States $0.048B 25.30
Ampio Pharmaceuticals (AMPE) United States $0.047B 0.00
KemPharm (KMPH) United States $0.040B 0.00
Capnia (SLNO) United States $0.040B 0.00
Heat Biologics (HTBX) United States $0.040B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.039B 0.00
Avenue Therapeutics (ATXI) United States $0.038B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.035B 0.00
ProPhase Labs (PRPH) United States $0.034B 3.84
Onconova Therapeutics (ONTX) United States $0.034B 0.00
IsoRay (ISR) United States $0.033B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.032B 0.00
Jaguar Animal Health (JAGX) United States $0.027B 0.00
Biomerica (BMRA) United States $0.027B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.026B 0.00
Citius Pharmaceuticals (CTXR) United States $0.026B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.026B 9.40
Lipocine (LPCN) United States $0.026B 0.00
Xenetic Biosciences (XBIO) United States $0.025B 0.00
HANCOCK JAFFE (HJLI) United States $0.025B 0.00
Can-Fite Biopharma (CANF) Israel $0.025B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.023B 0.00
Aviragen Therapeutics (VXRT) United States $0.023B 0.00
ESSA Pharma (EPIX) Canada $0.021B 0.00
NanoViricides (NNVC) United States $0.021B 0.00
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.019B 0.00
Cyanotech (CYAN) United States $0.019B 0.00
Shineco (TYHT) China $0.018B 1.81
Aradigm (ARDM) United States $0.018B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.017B 0.00
Regulus Therapeutics (RGLS) United States $0.016B 0.00
Midatech Pharma (MTP) United Kingdom $0.016B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.015B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.014B 0.00
Skyline Medical (AIPT) United States $0.012B 0.00
OncoGenex Pharmaceuticals (ACHV) United States $0.011B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.010B 0.00
Pain Therapeutics (PTIE) United States $0.009B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.008B 0.00
PharmAthene (ALT) United States $0.007B 0.00
Apricus Biosciences (APRI) United States $0.007B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.007B 0.00
Bio-Path Holdings (BPTH) United States $0.006B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.006B 0.00
Bio Blast Pharma (ORPN) Israel $0.005B 0.00
Intellipharmaceutics (IPCI) Canada $0.003B 0.00
RXi Pharmaceuticals (RXII) United States $0.002B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00